HUT54060A - Process for producing pharmaceutical compositions with antiviral or antibacterial effect - Google Patents

Process for producing pharmaceutical compositions with antiviral or antibacterial effect

Info

Publication number
HUT54060A
HUT54060A HU883981A HU398188A HUT54060A HU T54060 A HUT54060 A HU T54060A HU 883981 A HU883981 A HU 883981A HU 398188 A HU398188 A HU 398188A HU T54060 A HUT54060 A HU T54060A
Authority
HU
Hungary
Prior art keywords
antiviral
pharmaceutical compositions
antibacterial effect
producing pharmaceutical
composition
Prior art date
Application number
HU883981A
Other languages
English (en)
Other versions
HU204710B (en
HU883981D0 (en
Inventor
Witold Kiczka
Original Assignee
Nika Health Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nika Health Products Inc filed Critical Nika Health Products Inc
Publication of HU883981D0 publication Critical patent/HU883981D0/hu
Publication of HUT54060A publication Critical patent/HUT54060A/hu
Publication of HU204710B publication Critical patent/HU204710B/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HU883981A 1988-05-26 1988-05-26 Process for producing pharmaceutical compositions having antiviral and antibacterial effect HU204710B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17858888A 1988-05-26 1988-05-26
PCT/US1988/001785 WO1989011294A1 (en) 1988-05-26 1988-05-26 Antiviral or antibacterial compound and method of use
OA59731A OA09785A (en) 1988-05-26 1990-01-26 Antiviral or antibacterial compound and method of use

Publications (3)

Publication Number Publication Date
HU883981D0 HU883981D0 (en) 1990-12-28
HUT54060A true HUT54060A (en) 1991-01-28
HU204710B HU204710B (en) 1992-02-28

Family

ID=33162813

Family Applications (1)

Application Number Title Priority Date Filing Date
HU883981A HU204710B (en) 1988-05-26 1988-05-26 Process for producing pharmaceutical compositions having antiviral and antibacterial effect

Country Status (23)

Country Link
US (3) US5200182A (hu)
EP (1) EP0380484B1 (hu)
JP (1) JPH0649659B2 (hu)
AT (1) ATE93143T1 (hu)
AU (1) AU624331B2 (hu)
BG (1) BG60544B1 (hu)
CA (1) CA1335425C (hu)
CS (1) CS277030B6 (hu)
DK (1) DK173078B1 (hu)
ES (1) ES2011577A6 (hu)
FI (1) FI900412A0 (hu)
HK (1) HK42394A (hu)
HU (1) HU204710B (hu)
IL (1) IL90092A (hu)
LV (1) LV10054B (hu)
MA (1) MA21560A1 (hu)
MW (1) MW390A1 (hu)
OA (1) OA09785A (hu)
PH (1) PH26284A (hu)
RU (1) RU2092183C1 (hu)
WO (1) WO1989011294A1 (hu)
YU (1) YU109289A (hu)
ZA (1) ZA893382B (hu)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU624331B2 (en) * 1988-05-26 1992-06-11 Nika Health Products Ltd. A composition having as its active ingredient lysozyme or ribonuclease dimer in a pharmaceutically acceptable carrier
JP2732515B2 (ja) * 1990-01-08 1998-03-30 ニカ ヘルス プロダクツ リミテッド リボヌクレアーゼ二量体の製造方法
US5989880A (en) 1990-01-08 1999-11-23 Nika Health Products Ltd. Method of preparing lysozyme dimers
PL173978B1 (pl) * 1992-07-13 1998-05-29 Nika Health Products Ltd Sposób oddziaływania na wydzielanie cytokin w hodowli limfocytów krwi obwodowej
CH682541A5 (de) * 1992-06-23 1993-10-15 Urs Viktor Dr Wirth Biochemische Inaktivierung von RNA-Viren.
US6183742B1 (en) 1992-07-13 2001-02-06 Nika Health Products, Limited Applications of lysozyme dimer
DZ1964A1 (fr) * 1995-01-13 2002-10-15 Nika Health Products Ltd Nouvelle applications d'un dimère de lysozyme.
GB2304048A (en) * 1995-08-12 1997-03-12 John William Carson Medicament containing saliva extract
US6123937A (en) * 1997-03-14 2000-09-26 Nika Health Products, Limited Applications of lysozyme dimer
US7338936B2 (en) * 2000-11-28 2008-03-04 House Ear Institute Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
US6716813B2 (en) * 2000-11-28 2004-04-06 House Ear Institute Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
JP2002187853A (ja) * 2000-12-21 2002-07-05 Shinei Ferumentekku:Kk 動物の乳頭除菌剤および菌環境改善方法
DE10210285A1 (de) * 2002-03-08 2003-11-13 Medigene Ag Reversibles Toxin und seine Verwendung
US8470315B2 (en) 2004-04-13 2013-06-25 Quintessence Biosciences, Inc. Non-natural ribonuclease conjugates as cytotoxic agents
US20050244402A1 (en) * 2004-04-30 2005-11-03 Villanueva Julie M Absorption of pain-causing agents
US7348301B2 (en) * 2006-02-16 2008-03-25 Buckman Laboratories International, Inc. Lysozyme-based method and composition to control the growth of microorganisms in aqueous systems
JP2009541333A (ja) * 2006-06-23 2009-11-26 クインテセンス バイオサイエンシーズ インコーポレーティッド 修飾リボヌクレアーゼ
EP2049151A4 (en) 2006-07-17 2010-03-24 Quintessence Biosciences Inc METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER
CA2679939A1 (en) * 2007-03-02 2008-09-12 Stefano Ferrari Composition and method for treating papilloma virus and equine sarcoids
WO2009036000A2 (en) * 2007-09-11 2009-03-19 University Of Maryland, Baltimore Methods of treating a microbial infection by modulating rnase-l expression and/or activity
WO2009048909A1 (en) * 2007-10-08 2009-04-16 Quintessence Biosciences, Inc. Compositions and methods for ribonuclease-based therapies
CN102227443B (zh) 2008-10-01 2014-05-14 昆特森斯生物科学公司 治疗性核糖核酸酶
WO2010099182A1 (en) * 2009-02-25 2010-09-02 Board Of Regents Of The University Of Nebraska Activated creatinine and precursors as antibacterial agents, compositions and products containing such agents and uses thereof
NZ600269A (en) 2009-05-20 2014-02-28 Dec Int Nz Ltd Delivery device for treatment of mastitis
EP2457576B1 (en) 2010-11-29 2020-07-08 Eurochit Danuta Kruszewska Lactobacillus reuteri strain for use in the medical and veterinary prophylaxis and treatment of metabolic syndrome or infections
RU2548803C2 (ru) * 2011-11-28 2015-04-20 Общество с ограниченной ответственностью " Фарматренд" ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ ЛЕЧЕНИЯ ГЛАЗНЫХ ИНФЕКЦИЙ P. Aeruginosa, СОДЕРЖАЩАЯ РЕКОМБИНАНТНЫЙ ЛИЗОЦИМ
RU2509801C2 (ru) * 2012-03-22 2014-03-20 Борис Михайлович Куриненко СПОСОБ ИСПОЛЬЗОВАНИЯ РИБОНУКЛЕАЗЫ Bacillus intermedius
EP2674162A1 (en) 2012-05-29 2013-12-18 Danuta Kruszewska Nanoproduct comprising lactobacillus reuteri dan080 useful in prophylaxis and medicine, both human and veterinary and medical use of the same
WO2013180585A1 (en) 2012-05-29 2013-12-05 Danuta Kruszewska Nanoproduct comprising lactobacillus reuteri dan080 useful in prophylaxis and medicine, both human and veterinary and medical use of the same
RU2504397C1 (ru) * 2012-10-25 2014-01-20 Леонид Леонидович Клопотенко Фармацевтическая композиция, содержащая фермент рибонуклеазу и глицирризиновую кислоту или ее соли: глицирризинат аммония, или дикалия, или тринатрия
US9573980B2 (en) 2013-03-15 2017-02-21 Spogen Biotech Inc. Fusion proteins and methods for stimulating plant growth, protecting plants from pathogens, and immobilizing Bacillus spores on plant roots
WO2014152678A1 (en) 2013-03-15 2014-09-25 University Of Massachusetts Compositions and methods for delivering agents to the central nervous system
CN106029089B (zh) * 2014-02-21 2020-12-29 丘比株式会社 诺如病毒灭活剂及其制造方法
WO2016017784A1 (ja) * 2014-07-31 2016-02-04 キユーピー株式会社 含水流動状組成物及びその製造方法、並びに、リゾチーム加工品及び／又はその塩並びにその製造方法
BR122023020794A2 (pt) 2014-09-17 2024-01-23 Spogen Biotech Inc. Bactéria de bacillus recombinante e sua formulação
LV15071B (lv) * 2015-07-14 2016-02-20 Rīgas Stradiņa Universitāte Kompozīcija subklīniska mastīta ārstēšanai govīm
RU2634264C1 (ru) * 2016-09-19 2017-10-24 Александр Ливиевич Ураков Крем-молочко для лечения опоясывающего лишая
KR102470362B1 (ko) 2016-12-28 2022-11-25 디아이씨 가부시끼가이샤 분산체 및 그것을 사용한 잉크젯용 잉크 조성물, 광변환층, 및 액정 표시 소자
BR112020005730A2 (pt) 2017-09-20 2020-10-20 Spogen Biotech Inc. proteínas de fusão, membro da família bacillus cereus, fragmentos de exosporium, formulação, semente de planta e métodos para estimular o crescimento de plantas e para entregar uma enzima
EP4003300A4 (en) * 2019-07-26 2023-06-28 Infinant Health, Inc Nutritive compositions with bioactive proteins

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1268M (fr) * 1961-06-29 1962-04-24 Puiseux Médicament antimitotique et antiviral.
FR4020M (hu) * 1965-01-29 1966-03-21
DE1517751C3 (de) * 1965-07-08 1975-02-27 Eisai Co., Ltd., Tokio Verfahren zum Verhindern der Bildung von flockigen Lysozym- und/oder Lysozymsalzniederschlägen in wässrigen Lösungen, die Lysozym und/oder Lysozymsalze enthalten
DE1545644A1 (de) * 1965-12-06 1969-08-07 Boehringer Sohn Ingelheim Verfahren zur Herstellung von neuen quaternaeren Scopolammoniumsalzen
GB1110504A (en) * 1966-03-18 1968-04-18 Prodotti Antibiotici Spa Pharmaceutical compositions
US4221794A (en) * 1979-06-21 1980-09-09 Newport Pharmaceuticals International, Inc. Method of imparting immunomodulating and antiviral activity
US4510144A (en) * 1981-08-26 1985-04-09 Newport Pharmaceuticals International Methods of imparting immunomodulating activity with dihydrothiazolo purine derivatives
EP0187705A3 (en) * 1985-01-08 1988-05-11 Norwich Eaton Pharmaceuticals, Inc. Imidazo(4,5-f)quinolines useful as immunomodulating agents
US4739046A (en) * 1985-08-19 1988-04-19 Luzio Nicholas R Di Soluble phosphorylated glucan
US4744984A (en) * 1985-10-08 1988-05-17 Vetrepharm Research, Inc. Antiviral immunotherapeutic agent and preparation thereof
AU624331B2 (en) * 1988-05-26 1992-06-11 Nika Health Products Ltd. A composition having as its active ingredient lysozyme or ribonuclease dimer in a pharmaceutically acceptable carrier

Also Published As

Publication number Publication date
US6099835A (en) 2000-08-08
BG60544B1 (en) 1995-08-28
FI900412A0 (fi) 1990-01-25
MW390A1 (en) 1990-11-14
CS318089A3 (en) 1992-05-13
ZA893382B (en) 1991-01-30
US5466449A (en) 1995-11-14
IL90092A (en) 1995-03-30
AU624331B2 (en) 1992-06-11
HK42394A (en) 1994-05-13
CA1335425C (en) 1995-05-02
JPH03504121A (ja) 1991-09-12
PH26284A (en) 1992-04-10
WO1989011294A1 (en) 1989-11-30
RU2092183C1 (ru) 1997-10-10
YU109289A (en) 1991-08-31
DK173078B1 (da) 1999-12-20
US5200182A (en) 1993-04-06
CS277030B6 (en) 1992-11-18
BG91270A (bg) 1993-12-24
EP0380484A1 (en) 1990-08-08
DK16890A (da) 1990-01-22
JPH0649659B2 (ja) 1994-06-29
OA09785A (en) 1994-04-15
AU1940888A (en) 1989-12-12
MA21560A1 (fr) 1989-12-31
EP0380484B1 (en) 1993-08-18
HU204710B (en) 1992-02-28
ES2011577A6 (es) 1990-01-16
DK16890D0 (da) 1990-01-22
LV10054A (lv) 1994-05-10
LV10054B (en) 1995-02-20
HU883981D0 (en) 1990-12-28
ATE93143T1 (de) 1993-09-15

Similar Documents

Publication Publication Date Title
HUT54060A (en) Process for producing pharmaceutical compositions with antiviral or antibacterial effect
MY110734A (en) Improvements in or relating to dioic acids.
CA2068324A1 (en) Metal-peptide compositions and methods for stimulating hair growth
CA2118121A1 (en) Methods and compositions for the treatment of diseases with interferon while reducing side effects
AU6649996A (en) Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
AU693833B2 (en) Products containing G-CSF and TNF binding protein
AU2840889A (en) Method of treating haematologic diseases and pharmaceutical compositions to be used therefor
EP0813409A4 (en) TREATMENT OF DISEASES CAUSED BY THE CYTOKIN GROWTH FACTOR
HUT58037A (en) Process for producing n-2,3-butadienyl tri- and tetraaminoalkane derivatives
ZA929947B (en) Method of imparting antimicrobial activity to an opthalmic composition.
HUT68007A (en) Pharmaceutical compositions for preventing and treating retinal diseases and process for preparing them
IE870577L (en) Topical amide preparation
MY106984A (en) Antiviral or antibacterial composition and method of use.
ES8308884A1 (es) Procedimiento para la preparacion de nuevas imidazo(1,2-a)pirimidinas.
GEP19971029B (en) Antiviral or antibacterial compound and method of use thereof
AU7373196A (en) Combination of temozolomide and alpha-ifn for the treatment of advanced cancer
GR1001006B (el) Μεθοδος παρασκευης και χρησιμοποιησεως αντιιικων η αντιβακτηριακων συνθεσεων.
AU4259193A (en) Medicament for the gene-therapeutic treatment of human beings, animals and plants, especially to block virus multiplication and carcinogenes and process for producing the medicament
MY104932A (en) Immunomodulatory azaspiranes
AU2582588A (en) Pharmaceutical compositions with anti-cancer activity and method for the treatment of cancer
HU895238D0 (en) Process for the preparation of pharmaceutical composition suitable for the treatment of pyogenous skin diseases

Legal Events

Date Code Title Description
HPC4 Succession in title of patentee

Owner name: NIKA HEALTH PRODUCTS LTD., LI